Shimmick Corporation Announces Second Quarter 2026 Results

Shimmick Corporation reported Q2 2026 consolidated revenue of $107 million and gross margin of 12%, citing noncore project wind-down and efficiency gains. Backlog rose to $991 million with 1.4x book-to-burn. Full-year 2026 guidance updated to revenue of $525 million to $575 million and adjusted EBITDA of $15 million to $30 million.

The U.S. Army Corps of Engineers terminated Shimmick from a $309 million Chickamauga Dam lock chamber contract, alleging the contractor failed to prosecute work diligently, maintain the schedule and correct deficiencies. The contract required completion by Jan. 27, 2026. The Corps said the overall project costs about $954 million and targets an operational navigation lock in 2028. Shimmick disputes the termination and plans to appeal within 90 days.

Waste Connections (WCN) reported Q3 revenue of $2.64B, beating estimates by 1.2%, and adjusted EPS of $1.58, beating by 3.9%. The company raised its full-year revenue guidance to $10.09B. Operating margin expanded to 20.5% from 17.9% YoY. Management highlighted margin expansion from pricing discipline, landfill volume recovery, and sustainability investments, including RNG facilities. The board approved a 10% dividend increase and $1B in share repurchases.

Bloom Energy (BE) shares fell 11% on Oct. 23 despite beating Q3 earnings estimates and raising its 2026 outlook. The company reported adjusted earnings of $0.94 per share and revenue of $1.24 billion, both above expectations. However, negative free cash flow and broader market sentiment weighed on the stock. Analysts remain divided on price targets, with JPMorgan lowering its target to $292 and Morgan Stanley raising it to $335.

CACI reported Q3 revenue of $2.47B, missing estimates by 1.4%, but beat EPS and EBITDA expectations. The company raised full-year revenue and EPS guidance. Margins improved due to higher-margin technology contracts, and backlog remained steady at $34B. Growth was driven by defense and space contracts, with new manufacturing centers supporting future production.

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.